Assessing the utilization of the decision to implement a palliative goal for the treatment of cancer patients during the last year of life at Helsinki University Hospital : a historic cohort study by Hirvonen, Outi M. et al.
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=ionc20
Acta Oncologica
ISSN: 0284-186X (Print) 1651-226X (Online) Journal homepage: https://www.tandfonline.com/loi/ionc20
Assessing the utilization of the decision to
implement a palliative goal for the treatment
of cancer patients during the last year of life at
Helsinki University Hospital: a historic cohort
study
Outi M. Hirvonen, Riikka-Leena Leskelä, Lotta Grönholm, Olli Haltia, Antti
Rissanen, Kristiina Tyynelä-Korhonen, Eeva K. Rahko, Juho T. Lehto & Tiina
Saarto
To cite this article: Outi M. Hirvonen, Riikka-Leena Leskelä, Lotta Grönholm, Olli Haltia, Antti
Rissanen, Kristiina Tyynelä-Korhonen, Eeva K. Rahko, Juho T. Lehto & Tiina Saarto (2019):
Assessing the utilization of the decision to implement a palliative goal for the treatment of cancer
patients during the last year of life at Helsinki University Hospital: a historic cohort study, Acta
Oncologica, DOI: 10.1080/0284186X.2019.1659512
To link to this article:  https://doi.org/10.1080/0284186X.2019.1659512
Published online: 06 Sep 2019.
Submit your article to this journal 
Article views: 36
View related articles 
View Crossmark data
ARTICLE
Assessing the utilization of the decision to implement a palliative goal for the
treatment of cancer patients during the last year of life at Helsinki University
Hospital: a historic cohort study
Outi M. Hirvonena,b , Riikka-Leena Leskel€ac, Lotta Gr€onholmd, Olli Haltiae, Antti Rissanenc,
Kristiina Tyynel€a-Korhonenf, Eeva K. Rahkog, Juho T. Lehtoh and Tiina Saartod,i
aDepartment of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland; bDepartment of Clinical Oncology, University of
Turku, Turku, Finland; cNordic Healthcare Group, Helsinki, Finland; dDepartment of Palliative Care, Comprehensive Cancer Center, Helsinki
University Hospital, Helsinki, Finland; eTuusula Health Care Centre, Tuusula, Finland; fCenter of Oncology, Kuopio University Hospital,
Kuopio, Finland; gDepartment of Clinical Oncology, Oulu University Hospital, Oulu, Finland; hDepartment of Oncology, Palliative Care Unit,
Tampere University Hospital and Faculty of Medicine and Health Technology, University of Tampere, Tampere, Finland; iDepartment of
Palliative Care, Comprehensive Cancer Center, University of Helsinki, Helsinki, Finland
ABSTRACT
Background: To avoid aggressive treatments at the end-of-life and to provide palliative care (PC),
physicians need to terminate futile anti-cancer treatments and define the palliative goal of the treat-
ment in time. This single center study assesses the practices used to make the decision that leads to
treatment with a palliative goal, i.e., the PC decision and its effect on anti-cancer treatments at the
end of life.
Material and methods: Patients with a cancer diagnosis treated in tertiary hospital during 1st January
2013 – 31st December 2014 and deceased by the end of 2014 were identified in the hospital database
(N¼ 2737). Of these patients, 992 were randomly selected for this study. The PC decision was screened
from patient records, i.e., termination of cancer-specific treatments and a focus on symptom-cen-
tered PC.
Results: The PC decision was defined in 82% of the patients during the last year of life (49% >30days
and 33% 30days before death, 18% with no decision). The median time from the decision to death
was 46days. Systemic cancer therapy was given during the last month of life in 1%, 36% and 38%
(p< .001) and radiotherapy 22%, 40% and 31% (p¼ .03) cases, respectively; referral to a PC unit was
made in 62%, 22% and 11%, respectively (p< .001). In logistic regression analyses younger age, shorter
duration of the disease trajectory and type of cancer (e.g., breast cancer) were associated with a lack
or late timing of the PC decision.
Conclusion: The decision to initiate a palliative goal for the treatment was frequently made for cancer
patients but occurred late for every third patient. Younger age and certain cancer types were associ-
ated with late PC decisions, thus leading to anti-cancer treatments continuing until close to the death
with low access to a PC unit.
ARTICLE HISTORY
Received 16 April 2019
Accepted 15 August 2019
Background
Anti-cancer treatments may have a detrimental effect on the
quality of life of fragile cancer patients. Aggressive treat-
ments during end-of-life (EOL) also impose considerable
costs on health care systems [1]. Even though treatment
practices may differ between countries, studies from the US
and Canada suggest that the trend for aggressive EOL cancer
care is increasing [2,3]. Proposed standard benchmarks for
‘not overly aggressive cancer care’ include less than 10% of
patients receiving chemotherapy 14 days prior to death and
less than 2% of patients starting a new chemotherapy regi-
men 30 days prior to death [4]. The response to preceding
with anti-cancer treatments in advanced stages of cancer is
often uncertain whereas the toxicity increases the decline in
performance status. In order to avoid futile treatments at the
EOL, the treatment focus should be on symptom-centered
PC rather than on life-prolongation.
There is no clear agreement on the indicators of the over-
use of radiotherapy during the final weeks of life because of
its palliative nature in some cases. However, it has been sug-
gested that radiotherapy administered during the last 14 or
30 days of life might be a useful quality indicator [5] as there
is often insufficient time to reach a response.
The utilization of EOL chemotherapy and radiotherapy has
previously been investigated [6–22], but there are no studies
on the impact of PC decision-making and timing on anti-can-
cer treatments at the EOL.
In the present study, we determined the prevalence and
timing of PC decision in relation to the use of anti-cancer
treatments during the last year of life. The secondary aim
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was to investigate which factors affected the deci-
sion-making.
Material and methods
Cohort selection
Patients with a cancer diagnosis (ICD-10 C00-C96) treated in
the Department of Oncology during 1 January .2013–31
December 2013 and deceased by 31 December 2014 were
identified (N¼ 2737) from the Helsinki University Central
Hospital (HUCH) database. Of these patients, 992 were ran-
domly selected for the study cohort. The final study sample
consisted of 949 patients, after 43 patients were excluded
because their primary cause of death was other than cancer
or they were pediatric (<18-year old) cancer patients.
This historic registry-based study was done with the per-
mission of the authorities of HUCH. According to the Finnish
registration for research, no ethics committee approval
was needed.
The majority of Finnish cancer patients are initially eval-
uated at public university and central hospitals. HUCH is one
of the five university hospitals in Finland and provides cancer
care for approximately 1.6 million residents in Southern
Finland. During the time of this study, the HUCH Department
of Oncology was responsible for the radiation therapy treat-
ments of all cancer patients and the systemic cancer treat-
ments of all except pediatric, hematological, gynecological
and lung cancer patients; these patients received systemic
therapy in other departments. In the Department of
Oncology, there is a PC outpatient unit, but municipalities
are responsible for EOL care. Early integrated PC was not sys-
tematically organized at the time of the study.
Data sources and collection
The cohort of patients and their respective clinical informa-
tion were identified from electronic medical records. The
patient-level data included age, gender, and cancer diagno-
sis, oncological systemic treatments, radiation therapy, visits
to the PC unit, PC decision (date) and date of death.
Patients were divided into 13 diagnosis groups: (i) head
and neck cancers, (ii) upper gastro-intestinal (GI) cancers, (iii)
colorectal cancers, (iv) lung cancer, (v) melanoma and other
skin cancers, (vi) breast cancer, (vii) gynecological cancers,
(viii) prostate cancer, (ix) sarcomas, (x) cancers of the urinary
tract, (xi) primary CNS malignancies, (xii) lymphomas and
(xiii) others. When a deceased patient had more than one
malignancy, the cancer diagnosis was recorded in accord-
ance with the primary cause of death. The primary cause of
death was collected from the death certificates of the
national death certificate registry of Statistics Finland.
Most data used in this study was available in a structured
format, but some information was manually derived from the
medical records, e.g., the PC decision. The two researchers
reviewed all medical records according to the study protocol.
The consistency of the derived recordings was randomly
cross-checked. One researcher is a PhD and a specialist in
medical oncology and the other is a PhD student and a gen-
eral practitioner. Due to the nature of the data, there were
no missing values: diagnoses, dates and treatments given to
the patients are mandatory information to be recorded.
Palliative care decision and period
The PC decision, i.e., the decision to terminate life prolong-
ing anti-cancer treatments and focus on symptom centered
PC, is made by the oncologist responsible for the care of the
patient. The PC period was initiated by the PC decision and
defined as the period of time after termination of cancer-
specific chemotherapy or biological treatments. However,
endocrine treatment could continue during the palliative
period, e.g., LHRH analog for prostate cancer patients. In
addition, short courses of palliative radiotherapy, e.g., to
relieve pain were allowed. A search for the PC decision was
made in the medical records of all patients. The decision was
recorded if there was an explicit and clear mention of it in
medical records.
Patients were divided into three groups based on the tim-
ing of the PC decision: (1) no explicit PC decision, (2) the PC
decision made during the last 30 days before death and (3)
the PC decision made more than 30days before death. The
variables studied for each segment were: a visit to the pallia-
tive care (PC) unit and the last systemic cancer treatment
and radiation therapy given before death. The date of the
last radiation therapy was defined as the date of the last
fraction and for systemic cancer treatment the last date of
the treatment administered in hospital. With orally adminis-
tered systemic cancer treatment, the last day of treatment
was defined as the date when the oncologist recorded the
termination of the treatment in the medical records.
Statistical analysis
Descriptive statistics such as means and medians were used
for patient characteristics. The influence of the PC decision
on treatments was studied by testing the difference between
the three groups with cross-tabulation. The statistical signifi-
cance of the differences of the distributions was tested with
a chi-squared test. A one-way ANOVA was used to analyze
whether the age groups significantly differed depending on
the duration of time between the PC decision and death.
ANOVA was also used to analyze pairwise whether the three
groups of patients (based on timing of the PC decision) dif-
fered with respect to receiving radiation therapy before
death. The same analysis of differences in systemic cancer
treatments before death was done using the Kruskall-Wallis
test because the variances in the groups were not equal. A
logarithmic transformation was performed to normalize the
distribution of time between the PC decision and death. A
logarithmic regression model was built to show the factors
associated to the PC decision. The dependent variable was
defined as whether the PC decision was made earlier than
30 days prior to death or not. The variables tested in the
model were age, cancer diagnosis and time from diagnosis
to death. Both age and time from diagnosis to death were
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standardized (average ¼ 0, stdev ¼1) to normalize the distri-
butions. Gender was not included due to its perfect correl-
ation with gender specific cancer diagnoses. Two-sided p
values less than .05 were accepted as statistically significant.
All analyses were conducted with SPSS (version 25).
Results
There were 949 patients in the final sample, out of which
53% were male (Table 1). The key characteristics of the
patient population are presented in Table 1.
Decision for PC was made >30 d and 30 d before death
in 49% and 33% of the patients, respectively. No PC decision
was made for 18% of the patients.
The distribution of patients in the three groups varied
depending on the cancer diagnosis (Table 2). Most often the
PC decisions were made earlier than 30days prior to death for
patients with colorectal cancer, sarcomas and prostate cancer,
while the decisions were typically made within the last month
before death for breast and skin cancer patients. For 61% of
head and neck cancer patients, a PC decision was made at
any point in time. The differences in the distributions between
cancers were statistically significant (p¼ .02).
The distribution of patients into the three groups depend-
ing on the patient’s age at death is presented in Table 3.
There were statistically significant differences between the
age groups (F-value 5,186, p value< .001), but only the
group of patients >80-year old were statistically different
from other age groups (p< .01 for all pairwise comparisons).
Characteristics associated with a PC decision made
>30 days before death in a logarithmic regression model are
shown in Table 4. As the proportion of patients receiving a
PC decision >30 d before death was lowest in breast cancer
Table 1. Characteristics of the patient population.
Characteristic
Gender, n (%) Male 499 (52.6%)
Female 450 (47.4%)
Palliative care decision made, N (%) 773 (81%)
Median IQR
Age at death (years) 68 y 61–75 y
Time from diagnosis to death 539 d 243–1133 d
(19 mos) (8–38 mos)
Time from diagnosis to palliative care decision 443 d 153–1057 d
(15 mos) (5–35 mos)
Time from the palliative care decision to death 46 d 16–131 d
(1.5 mos) (0.5–4.5 mos)
Time from the last systemic cancer treatment to death 78 d 37–155 d
(2.6 mos) (1.2–5.1 mos)
Time from the last dose of radiotherapy to death 74 d 27–174 d
(2.5 mos) (0.9–5.8 mos)
M: male; F: female; IQR: interquartile range; y: years; d: days; mos: months
Table 2. Time from palliative care decision to death in different cancer groups.
Cancer diagnosis
Time from the palliative care decision to death
N (% from total)>30 d 30 d No decision
Head and neck 36% 36% 29% 28 (3%)
Upper gastrointestinal 55% 32% 14% 218 (23%)
Colorectal 61% 25% 14% 123 (13%)
Lunga 47% 31% 23% 118 (12%)
Melanoma and other skin cancers 38% 44% 19% 32 (3%)
Breast 31% 46% 23% 106 (11%)
Gynecologicala 36% 32% 32% 28 (3%)
Prostate 57% 24% 19% 67 (7%)
Sarcomas 60% 23% 17% 30 (3%)
Urinary tract 52% 38% 10% 61 (6%)
Primary CNS malignancies 45% 28% 27% 60 (6%)
Lymphomas 41% 43% 16% 37 (4%)
Others 41% 34% 24% 41 (4%)
TOTAL 416 312 176 949
aOnly patients receiving radiotherapy are included.
Table 3. Time from PC decision to death in different age groups.
Age group >30 days, % (n) 30 days, % (n) No decision, % (n) Mean, days (SD)
20–40 years 36% (12) 39% (13) 24% (8) 78 d (120.3)
41–60 years 42% (85) 35% (72) 23% (46) 100 d (182.7)
61–70 years 46% (152) 32% (109) 22% (72) 95 d (150.4)
71–80 years 51% (136) 33% (88) 16% (42) 110 d (168.5)
>80 yearsa 67% (76) 26% (30) 7% (8) 165 d (259.6)
TOTAL 49% (461) 33% (312) 19% (176) 109 d (180.9)
aStatistically significant (p< .05) difference with other age groups.
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patients, we selected the breast cancer as the reference cat-
egory for cancer groups. A statistically significant positive asso-
ciation was found for age (OR 1.3) and number of days from
diagnosis to death (OR 1.2). Thus, the PC decision was more
probable >30days before death the older the patient and the
longer the disease trajectory. From the diagnoses, the odds
were highest for colorectal cancers and sarcomas (OR 5.2 and
OR 4.3, respectively), hence these diagnoses were associated
most often with the PC decision >30days before death.
Figure 1 illustrates the association between the PC deci-
sion and its timing to the last radiation therapy visit or last
course of systemic cancer treatment before death. The ana-
lysis was done only for the patients that received radiation
therapy (n¼ 468) or systemic cancer treatments (n¼ 580)
during the last year of life. Of these patients, 29% and 20%
received radiation therapy and systemic cancer treatment
during the last month of life, respectively. However, for those
receiving radiation therapy, the goal of the last treatment
was palliative for 87%. The majority of the patients who
received radiation therapy or systemic cancer treatment
during the last month did not have a PC decision or the
decision was made within the last month. Comparing the
distributions in Figure 1, the chi-squared test only indicated
a statistically significant difference in the distributions for the
systemic cancer treatments (p< .001 for systemic cancer
treatments and p¼ .03 for radiation therapy). Pairwise com-
parisons revealed that for radiation therapy the difference
between the three patient groups was statistically significant
only between those with a PC decision made over 30 days
prior to death and those with a PC decision within one
month of death (p¼ .003). For systemic cancer treatment,
the differences in the distributions were statistically signifi-
cant between those with a PC decision made over 30 days
prior to death and both other groups (p< .001). The differ-
ence between the two other patient groups, however, was
not statistically significant (data not shown).
Sixty-two percent of the patients with a PC decision made
>30 days before death visited the PC unit as compared to
22% of the patients with the decision 30 days and 11%
without the decision. The differences between the groups
were statistically significant (p< .001).
Discussion
In this assessment of EOL care at a Finnish university hos-
pital, a PC decision defining the symptom-centered goal of
the care was frequently made, but often occurred late in the
disease trajectory. Patients with no or a very late decision
received more aggressive cancer treatments at the EOL and
made infrequent visits to the PC unit. Age, duration of the
disease trajectory and type of cancer were associated with
the timing of the decision.
Frequency and timing of PC decision
According to previous studies, only a minority of patients
with a prognosis of less than one year, have discussed EOL
Table 4. Characteristics associated with a PC decision made > 30 days before
death in the logistic regression model: odds ratios and confidence intervals.
Characteristics Odds ratios 95% CI p Value
Diagnoses
Breast cancer (ref) 1
Sarcomas 5.2 2.11–12.59 <.001
Colorectal cancers 4.3 2.37–7.81 <.001
Upper gastrointestinal (GI) cancers 3.5 1.97–6.06 <.001
Prostate cancer 2.9 1.50–5.63 <.001
Cancers of urinary tract 2.9 1.43–5.69 .003
Primary CNS malignancies 2.8 1.38–5.73 .004
Lung cancer 2.5 1.35–4.61 .004
Others 2.0 0.91–4.41 .084
Lymphomas 1.9 0.85–4.42 .115
Gynecological cancers 1.8 0.70–4.46 .230
Head & Neck cancers 1.8 0.70–4.42 .228
Melanoma and other skin cancers 1.6 0.66–3.66 .318
Age (standardized) 1.3 1.16–1.54 <.001
Time from diagnosis to death (standardized) 1.2 1.02–1.39 .03
Breast cancer diagnosis is used as the reference value for the diagno-
sis variable.
Figure 1. Time between last radiation therapy and death (a) and time between last systemic cancer treatment and death (b) with respect to the timing of the
PC decision.
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care with their oncologist [23]. In the present study, a PC
decision was found in the medical records of 82% of the
patients, which is a relatively high figure. However, even
though discussions about the termination of anti-cancer
treatments were carried out prior to death in a majority of
the patients, the decision was only made at least a month
before death for half of the patients.
A PC decision was more likely to be made for older
patients with the threshold being patients over 80 years of
age. In a previous Finnish study [16], patients under the age
of 50 were more likely to receive IV chemotherapy during
the last months and weeks of life compared to older
patients. Likewise, Braga et al. [7] have shown the increased
probability of younger patients receiving chemotherapy dur-
ing the last three months of life. Although our results are in
line with these earlier studies, the difference was significant
only in the very elderly population (above 80 years) in
our study.
As well as the younger age of the patient, the chemosen-
sitivity of the tumor and thus the available alternative treat-
ment options have been found to correlate with the use of
chemotherapy during the last months of life [3,7,8,12].
Similarly, in the present study, among the breast cancer
patients the decision to terminate cancer-specific treatment,
i.e., making a PC decision was done late. On the other hand,
the short disease trajectory, like in head and neck cancer,
decreases the likelihood of early PC decision [24–26]. Thus, in
diseases with a very poor prognosis the integration of PC
should take place early, i.e., immediately after the diagnosis
of an advanced disease. For diseases with multiple treatment
options and a relatively long survival, PC should be intro-
duced at least when the treatment options diminish [27].
Impact of PC decision on cancer treatments in EOL
Chemotherapy late in life does not improve patient’s quality
of life [28], in fact it is quite the contrary; it has been shown
that a patient receiving palliative chemotherapy will most
likely require more admissions to hospital, have a lower
chance of dying at home, and may also have a shortened
survival time [9].
In this study, 20% of the patients received systemic cancer
treatment during the last month of life. This was in line with
another Finnish study [16] where 18% of the patients
received IV chemotherapy during the last month. The corre-
sponding figures during the last two weeks of life were 18%
in this study and 7% in the study by Rautakorpi et al. [16].
However, in the present study orally given chemotherapy
and biological treatments were also included, which could
explain the higher rate of patients receiving systemic treat-
ment at the EOL. In previous studies, the prevalence of anti-
cancer treatments one month before death have varied from
12% to 43% [2,7,9–15]. Comparison between the studies is,
however, challenging, as the health care systems, study
designs, and inclusion criteria vary. Nevertheless, according
to proposed standard benchmarks for ‘not overly aggressive
cancer care’, no more than 10% of patients should receive
chemotherapy 14 days prior to death [4]. Our results showed
that the timing of the PC decision has a distinct correlation
with the use of systemic anti-cancer treatments at EOL. If the
PC decision was left undone or postponed to the last month
of life the risk of aggressive cancer treatments during the
EOL was significantly higher compared to patients with an
early PC (38%, 36% and 1%, respectively). Interestingly, the
risk of aggressive treatment at EOL was as high with a late
PC decision as without it.
Thus, not only making the decision to switch to care with
a symptom-centered palliative goal is important but its tim-
ing is also of vital importance. An early decision enables not
only timely advance care planning and access to PC, but also
the termination of futile, and potentially quality of life reduc-
ing systemic anti-cancer treatments.
In the present study, 29% of the patients received radio-
therapy during the last month of life and 14% in the last
two weeks, respectively. The prevalence of radiotherapy in
the present study is somewhat higher than in the previous
studies. In another Finnish study from 2005 to 2013 [22], the
corresponding figures were 23% and 12%, respectively.
According to previous studies, the proportion of patients
receiving radiotherapy one month prior to death varied
between 5% and 12% [6,15,17–19]. Interestingly, there was
no difference in the number of radiotherapy treatments at
the EOL with regards to the timing of the PC decision. One
explanation for higher portion of patients getting radiother-
apy at the EOL in this study could be the high proportion
(87%) of palliative radiotherapy in the present population.
However, according to the study by Rautakorpi et al. nearly
half of the treatments given in the last two weeks were dis-
continued, the deterioration of the general condition being
the most common reason for the discontinuation [22]. In
addition, if radiotherapy is given very late, patients do not
obtain any benefit from the treatment [29,30].
Impact of PC decisions on visits in PC unit
Even though we did not study the quality of EOL care, refer-
ral to a PC unit could be considered as an indicator of better
EOL care [31–33]. In the present study, the earlier the deci-
sion of a palliative goal for the treatment was made the
more often the patient was referred to a PC unit (62% with
early, 22% with late and 11% with no PC decision). In HUCH,
the PC decision is made by the oncologist responsible for
the cancer treatments instead of a shared decision making
with the palliative team as during the study period no sys-
tematic early-integrated PC was offered in the center.
According to an international consensus, one of the indica-
tors required for decision making is referral to a palliative
team [27]. Our findings emphasize the importance of early
integration of PC to improve EOL care planning [31–34].
Limitations and strengths of the study
There are some limitations to our study. One limitation is the
retrospective nature of our study; the data was based on
hospital medical records. Any possible inaccuracies in the
records might also be reflected in the results. However, the
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information concerning the PC decision and the time it was
made was searched for manually and thus reliable. The other
limitation is the lack of data on the response to last anti-can-
cer therapies. Neither did we search for the treatment inten-
tion (curative or disease modifying) in systemic cancer
therapies at the EOL in relation to PC decision and its timing.
Due to the retrospective nature of the study, the data on the
quality of life and the need for palliative interventions is
missing. Furthermore, we were unable to control any varia-
bles outside medical records, such as patient’s socioeco-
nomic status or ethnic group. The strength of the study is
that it is a population-based real-life study with a relatively
large sample size. The study cohort was epidemiologically
representative of the prominent oncological diseases found
within the population. The information concerning the PC
decision made by the oncologists and its timing in relation
to death, in addition to the data on the referral to a PC unit
provided unique information about the decision making at
the end of life.
Conclusions
Our study revealed that for most cancer patients the PC deci-
sion as regards a symptom-centered palliative goal for their
care was made by the oncologists. However, the decision
was made very late. The lack of a PC decision or postponing
it to the last month of life reflected a significantly increased
risk for aggressive cancer treatments during the EOL and
delayed the access to PC services. Early-integrated PC should
be offered more systematically to ensure timely advanced
care planning and access to palliative and EOL care.
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